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Background: COVID-19 shows variability depending on ethnicity and environmental factors therefore one type of 
drug may not be effective in all the populations. Personalized medicine refers to tailoring the treatment in 
accordance with individual patients. In the current COVID-19 crisis can this therapy change the course of research 
and treatment? A study was conducted to investigate the number of physicians with knowledge about 
personalized medicine and if it was being applied into routine practice, to direct the use of P drug for COVID-19 
treatment. 
Methods: A cross-sectional survey was carried out at Khyber Girl’s Medical College Hayatabad. Respondents 
included 100 doctors of various specialties who were interviewed regarding the knowledge of personalized 
therapy for various diseases and their impact on treatment outcomes. They were investigated if according to their 
experience of tailoring, it could bring about better treatment outcomes for COVID-19. 
Results: Out of the total 100 89 (89%) doctors were routinely prescribing tailored treatment and believed that the 
COVID-19 research should be modified through personalization and genetics. 
Conclusion: Personalized therapy is more targeted hence brings about therapeutic benefits and it would ensure 
better therapeutic outcomes in COVID-19 cases. 
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Introduction 
 
COVID-19 is an ongoing global emergency.  As high 
as 15% of the infected individuals, develop the severe 
form of the disease. Coronaviruses are RNA encoded 
genetically diverse viruses that can use several species 
as hosts. The aftermath is the infections of the 
respiratory tract mainly and intestines. The typical 
symptoms are pyrexia, cough, myopathy ad 
breathlessness, however certain atypical symptoms 
such as vomiting and diarrhea have also been 
observed.1 The symptoms, however, are affected by 
several confounding variables, most prominently the 
co-morbid ailments e.g. diabetes, hypertension, 
asthma, pneumonia, obesity, etc.2,3 Also a variety of 
environmental and genotypic factors influences the 
disease phenotype, severity as well as mortality rate 
and fatality4 including variations and polymorphisms 
in several host proteins including enterocytes, 
pneumocytes, renal epithelial cells, immune cells, as 
well as cerebral neuronal cells, ethnicity, race, and 
gender of the host. The contemporary narratives 
regarding the disease are being upgraded via the 
continuous research and are narrowing down the 
individuals that are more susceptible not only to 
disease acquisition but also to the severity and 
mortality related to it. The blacks and African 
Americans have been noted not only to contract the 
disease at a higher frequency but also likely to suffer 
higher mortality.5 Besides, the Asian population is 
prone to the severity of the disease as the frequencies 
of related co-morbidities that exacerbate COVID-19 are 
higher among this population.6 Angiotensin-
converting enzyme-II acts as a receptor for the COV in 
the host cells. Its expression varies among different 
ethnic populations, warranting the differences in 
disease presentation among them.7 The data relative to 
ethnicity regarding COVID-19 needs to be expanded 
and further evidence is to be collected in this regard as 
the available evidence strongly shows a disparity in 
disease pattern and severity related to racial and 
ethnic differences. The concerns, however, go beyond 
just ethnicity and race. The type and locale of the 
residence, the socioeconomic backgrounds, cultures, 
and behaviors also matter as the lesser privileged 
individuals are prone to exposure as per their low 
immunity diets and the crowded residential 
arrangements.8 The research work is being carried out 
aiming several targets such as virulent factors of COV 
and the attachment sites and enzymes involved in the 
host. The data collected strongly suggests a more 
individualized approach to formulate personalized 
therapy for COVID-19. 
The personalized drug also known as a Preferred 
drug, Physician’s drug or a P drug9, is a drug tailored 
according to the individual patient requirements based 
on the drug efficacy, safety, suitability for the patient 
as well as the affordability so that the best response of 
the therapy is achieved.10 There exists variability in 
drug response to the traditional treatment protocols 
among several patients as a result of a variety of 
factors including age, gender, nutrition, health status, 
comorbid conditions, ethnicity, environmental factors, 
psychological factors, drug resistance, idiosyncrasy as 
well as the genetic makeup.11,18 The successful 
treatment in all such cases thus depends on the 
modifications in the patterns of prescription and 
management regimens for medical practitioners. 
Personalized medicine is an extension of the 
commonly applied traditional strategies to understand 
and treat the diseases but offers a much greater 
therapeutic precision.12,13 Talking specifically about 
COVID-19 and the knowledge of phenotypic 
disparities, physicians need to work beyond the 
previous one-size-fits-all model of prescription and 
move forward to make more efficacious and effective 
clinical decisions for each patient depending on the 
genetic as well as environmental factors. These 
strategic changes for pharmaceutical and diagnostic 
research are going to bring about marked 
improvements in the treatment outcomes.14,15 P Drug 
therapy for COVID-19 would be focused to treat the 
disease not only based on the signs and symptoms but 
also combining the knowledge and judgment of the 
physician linking with the individual patient profiles 
that would improve the therapeutic outcomes, 
decrease morbidity and mortality and also reduce 
trial-and-error prescribing, implement the use of safer 
drugs, avoid adverse drug effects, increase patient 
compliance and reduce the overall cost of the health 
care.16 
The main aim of this study was to hypothesize that 
there very ethnic and environmental disparities 
regarding COVID-19 and hence the individually 
targeted, personalized drug therapy would yield a 
reasonably predictive outcome, thus enhancing the 
widespread treatment benefits. To solidify the 
hypothesis a survey was carried out regarding the 
practice of personalized drug therapy among medical 
practitioners, and the benefits to the patients to 
incorporate clinical experience and opinions of these 
doctors on the implementation of personalized therapy 
for COVID-19 treatment.  
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Materials and Methods 
 
An international internet-based cross-sectional survey 
with online and in-person interviews was carried out 
from 1st Feb 2020 to 1st May 2020 in Khyber Girl’s 
Medical College Hayatabad after the approval from 
the ethical board postgraduate medical education 
block, Khyber Girl’s Medical College. The sample size 
was calculated using Cochran’s formula keeping p= 
0.89, 90% confidence interval with Z=1.645, and a 
precision of 0.05. The sample population was selected 
through a random sampling technique. The sample 
population consisted of a total of 100 doctors from 
Pakistan, India, UAE, UK, and USA. The doctors 
included general physicians as well as specialists. The 
inclusion criterion was practicing physicians while the 
non-practicing doctors were excluded from the study. 
Consent was taken from all the participants. 
Interviews were taken either directly or through phone 
prescribing practices, the experience with 
personalization of treatments, the probable role of 
personalization in COVID-19 therapeutic outcome 
and, their ideology regarding the need for this therapy 
and the benefits of personalization which would direct 
towards the benefit in cases of COVID-19 therapeutics. 
 
Statistical Analysis: The entry and analysis of the data 
were one via the 23rd version of SPSS. The frequency 
of knowledge, attitude, and practice of personalized 
drug therapy was calculated as percentages and 




The assessment was made based on three parameters, 
the knowledge of P drug, the practice of P drug in 
prescribing, and the attitude towards the benefits of 
personalized therapy and its probable role for COVID-
19 therapeutics. 
 
Knowledge of P Drug: 
Out of the total 100 doctors, 89 (89.00%) knew about 
personalized therapy, its importance, and its utility in 
Table 1. 
Table 1: Number of participants with the knowledge 




Number             
(Percentage) 
Unaware 
Number                  
(Percentage) 
Definition 89 89% 11 11% 
Rationale 84 84% 16 16% 
Objectives 84 84% 16 16% 
Components 80 80% 20 20% 
Importance 89 89% 11 11% 
 
The practice of Personalized Therapy: 
A total of 89 (89 %) of the doctors were prescribing 
personalized therapy in routine prescribing in Table 2.  
Table 2: Number of participants practicing 
personalized therapy 
P Drug Practice Prescribing P Drug 
Number     Percentage       
Currently prescribing P 
Drug 
89 89% 
Prescribing P Drug as 
per knowledge 
87 87% 
Prescribing P Drug just 





Attitude towards P Drug Therapy: 
A total of 89 (89%) physicians tailoring the therapy 
commented that personalizing the treatment has 
shown massive improvements in the treatment 
outcomes, uncomplicated recoveries and improved the 
overall therapeutic efficacy, therefore, the research of 
COVID-19 therapeutics needed to be individualized in 
Table 3. 
Table 3: Attitude of the participants towards 
Personalized Medicine for COVID-19 treatment 
Attitude Towards 
Personalized Medicine 
Number    Percentage 




Interested in practicing 
P Drug 
89 89% 





Agree that the P Drug 
therapy is the need of 
the hour for COVID-19 
88 88% 
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Ready to disseminate 
other physicians in the 
P Drug practice 
84 84% 
 
The 89 participants were inquired about the type of 
personalization to be followed that could prove to be 
beneficial for COVID-19 management to which 
different parameters were suggested by them in 
accordance with the knowledge of their routine 
prescribing outcomes in Tables 4 & 5. 
 




          Aware 
Number   Percentage 
FDA guidelines should be 
modified based on 
ethnicity 
45 50.56.% 





Drugs should be tailored 
according to individual 
patient needs 
20 22.47% 
Drugs should be chosen in 
accordance with the genetic 
makeup 
12 13.48% 
Drug dosages need to be 
verified in accordance with 
the individual patients 
2 2.24% 
 
Table 5: Most important factor for COVID-19 P Drug 
Most important factor for 
Personalization 
 
Number   Percentage 
Affordability 03 3.37% 
Safety 10 11.23% 
Maximum practice outcome 
data 
14 15.73% 








The personalized drug therapy has evolved as the 
genomic information is being exceedingly utilized by 
the physicians not only in their research but also in the 
clinical work. The application of pharmaco-genetics 
for COVID-19 would be one step towards the goal of 
improved pharmaco-therapeutic management. To put 
the personalized therapy into use for routine practice, 
several hurdles lie ahead, however, that include the 
attitudes of the physicians towards tailoring of the 
treatment, lack of research directed towards the 
genetic makeup, the lack of knowledge and experience 
regarding the positive implications of personalization, 
and deficiency of data related to ethnic and genetic 
variations in the severity and pathophysiology of 
COVID-19. One of the main challenges is a lack of data 
representing the variations in the disease patterns 
based on genetic as well as environmental factors. Of 
the doctors inquired, 11% were unaware of 
personalized therapy. The previous studies have also 
shown unsatisfactory knowledge of P drug therapy 
among physicians.17 This warrants the need to 
familiarize the healthcare professionals with 
personalization of the therapy so that they can bring 
about related modifications in their current practice 
routine and research. 
Several physicians are comfortable with their routine 
prescribing practices. They believe it brings about an 
acceptable response so are unwilling to bring 
personalization into practice. It could either be the 
result of a lack of knowledge or being unaware of the 
therapeutic advantages that tailoring the treatment in 
accordance with the individual needs brings forth. 
However, majority of the doctors (who were not 
personalizing the therapy already) agreed that they 
need to their current practices and that the 
personalization is going to improve the treatment and 
hence the COVID-19 research needs to be directed this 
way as personalized therapeutics will be beneficial to 
both the patient and the healthcare system. The P Drug 
therapy has brought about remarkable improvements 
in the treatment outcomes for most of the diseases as 
per the experience and practice survey of the physician 
therefore, it most definitely is going to revolutionize 
the research regarding COVID-19 management.19,20 
The researchers have to apply the knowledge in their 
ongoing experiments and research. The respondents 
showed a good response to their utility of P Drug. Out 
of the 89% who were prescribing P drug, stated that 
the correct personalization based on genetics, safety, 
affordability, and environmental factors brings about 
marked improvement in therapeutic outcomes. The 
results from this survey indicate that researchers need 
to focus on the factors producing variability in 
COVID-19 responses, social interactions and 
discussions should be arranged frequently to ensure 
educational communications and learning for 
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clinicians, certain tools should be adopted that can 
direct the medical professionals towards gaining 
knowledge and therefore applying the personalized 
therapy. These may include workshops, seminars, 
educational discussions, and continuous knowledge 
update through events accredited by continuing 
medical education (CME). Furthermore, modern 
innovative systems and resources of knowledge of 
medical education including online, point-of-care tools 
should be encouraged, which ultimately leads to an 
improved and more effective utilization of not only the 
genetic information but also the other variables of 
tailoring the drug therapy for COVID-19.  
In regards to COVID-19 therapeutics, genetic 
polymorphisms should be the mainstay of the 
research. The first step could be the study and 
comparison of plasma samples from various patients 
who have recovered from the illness.21 The variations 
in their antibody profiles and immunity studies can 
reveal important parameters suggesting the 
requirement of an individualized approach for the 
ongoing research. The personalization will not only 
provide maximum benefits to the patients but will 
open new routes for the development of better 
therapeutic measures for COVID-19. The disease 
progression and severity also needs to be studied and 
compared among genetically variable populations, 
variable cultures, and social constructs as well as 
behavioral patterns to look for variations of the disease 
pattern and pathophysiology. Also, immunity profiles 
and co-morbidities need attention as they are known 
to enhance the severity and mortality of pandemics in 
the past.22 Coordinated efforts must be done to collect 
data regarding COVID-19 variability and in 
accordance to the knowledge already in hand, the 
ongoing work must be directed based on the ethnicity 
and environmental factors as the cure for one type of 
genetically similar individuals might not be as 
effective or effective at all in the other ethnically and 
environmentally different population. Last but not the 
least the knowledge based on the lines of 
polymorphisms should be communicated so it can be 




The results suggest a need for better strategies and 
guidelines for enhanced awareness of personalized 
medicine among researchers. Tailoring the therapy 
according to the patient’s age, sex, co-morbidities, 
ethnicity, and genetics would be a leap forward. Most 
of the doctors agreed that improving the 
understanding of P Drug for COVID-19 would lead to 
better therapeutic outcomes as variability is noted in 
the disease pattern based on ethnicity and 
environmental factors. All the healthcare professionals 
who had seen the positive outcomes of personalizing 
treatments were of the view that P drug therapy has to 
be the mainstay for COVID-19 therapy and it will 
improve and revolutionize the treatment outcomes. 
The physicians should be encouraged to carry out 
researches keeping in view the genetic variations. 
There is an urgent need collection of prospective data 
of various factors causing disease variability and 
awareness programs regarding personalized therapy 
and its predicted applicability to COVID-19 infections. 
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